Voya Investment Management LLC Has $15.29 Million Holdings in Glaukos Corporation $GKOS

Key Points

• Voya Investment Management LLC reduced its stake in Glaukos Corporation by 22.6%, selling 45,374 shares, while still holding 155,324 shares valued at approximately $15.3 million.
• Several hedge funds, including Wellington Management Group and Alliancebernstein, have increased their investments in Glaukos, with 99.04% of the company's stock held by institutional investors.
• Analysts have mixed ratings on Glaukos, with one upgrade to "strong-buy" from William Blair and an average target price of $124.83, following a report of better-than-expected earnings despite a negative net margin.

Voya Investment Management LLC trimmed its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 22.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,324 shares of the medical instruments supplier's stock after selling 45,374 shares during the period. Voya Investment Management LLC owned about 0.27% of Glaukos worth $15,287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Osterweis Capital Management Inc. purchased a new stake in shares of Glaukos during the first quarter worth $5,820,000. Inspire Investing LLC increased its position in Glaukos by 45.6% during the first quarter. Inspire Investing LLC now owns 3,958 shares of the medical instruments supplier's stock worth $390,000 after buying an additional 1,239 shares during the last quarter. Strs Ohio acquired a new position in Glaukos during the first quarter worth $955,000. Intech Investment Management LLC increased its position in Glaukos by 212.7% during the first quarter. Intech Investment Management LLC now owns 92,564 shares of the medical instruments supplier's stock worth $9,110,000 after buying an additional 62,963 shares during the last quarter. Finally, Bayforest Capital Ltd acquired a new position in Glaukos during the first quarter worth $141,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Down 2.8%

NYSE GKOS traded down $2.41 on Friday, reaching $83.43. The company had a trading volume of 1,721,400 shares, compared to its average volume of 720,302. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -50.56 and a beta of 0.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The company's fifty day moving average is $91.38 and its 200-day moving average is $94.68.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GKOS has been the topic of several analyst reports. Wells Fargo & Company increased their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Zacks Research downgraded Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. BTIG Research reaffirmed a "buy" rating and issued a $118.00 price target on shares of Glaukos in a research report on Wednesday, September 10th. William Blair raised Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Mizuho set a $130.00 price target on Glaukos in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $124.83.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.